

Mycobacterium Tuberculosis and Rifampicin Resistance Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing)

Testing as Treatment

Easy to Operate

Short Time

TB and RFP

WHO THE END TB STRATEGY

Ending TB is not just a public health problem, but a development challenge and opportunity. WHO's post-2015 End TB Strategy, adopted by the World Health Assembly in 2014, aims to end the global TB epidemic as part of the newly adopted Sustainable Development Goals.

It serves as a blueprint for countries to reduce TB incidence by 80%, TB deaths by 90%, and to eliminate catastrophic costs for TB-affected households by 2030.

PARAMETERS

Product features	Parameter	
Specimen Types	Sputum	
Technical Platform	Real-time PCR (One-tube fast release technology)	
Instruments	iPonatic II (S-Q31B)	
Targets Region	TB (IS6110,IS1081), <i>rpoB</i> gene (5 probes)	
TAT	43 min	
Internal Control	RNase P	
Sensitivity	Mycobacterium tuberculosis 1×10³ Bacteria/mL; Rifampicin resistance 1×10⁴ Bacteria/mL	

ORDER INFORMATION

Product Number	Product Name	Spec.
S3370E-12-P	Mycobacterium Tuberculosis and Rifampicin Resistance Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing)	Pre-packaged 12T/kit
Y1001E	Sample Diluent	24T,96T/Kit



ADDR.: No. 680, Lusong Road, Yuelu District, Changsha, Hunan Province, 410205, P.R.China

TEL.: +86-731-88883176-6116 **FAX**: +86-731-89736985

MAIL: info@sansure.com.cn / support@sansure.

WEB: www.sansureglobal.com

